Could a pill ease long COVID fatigue? new trial hopes to find out

NCT ID NCT06597396

Ongoing Symptom relief Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2a trial tests whether the drug abrocitinib can reduce severe fatigue in adults with Long COVID. About 46 people who were never hospitalized for COVID but now have long-term fatigue will take either 50 mg, 100 mg of abrocitinib, or a placebo daily for 12 weeks. Researchers will measure changes in fatigue and overall health using standard questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abrocitinib (a drug taken by mouth)
What this could lead to: If it works, this could point toward a treatment for severe fatigue in people with Long COVID.
What could go wrong: This is a small, early-phase trial with only 46 people. The drug may not improve fatigue more than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FATIGUE SYMPTOM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fatigue long COVID-19 post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FATIGUE SYMPTOM POST COVID CONDITION

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.